Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 179
- Registration Number
- NCT01278160
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Healthy
- Interventions
- Drug: placebo
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT01272973
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
Phase 3
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: placebo
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 846
- Registration Number
- NCT01272232
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Phase 3
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: placebo
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3731
- Registration Number
- NCT01272219
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 296
- Registration Number
- NCT01272193
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan
Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia AHaemophilia B
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12
- Registration Number
- NCT01272206
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 13
- Registration Number
- NCT01269606
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT01261767
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Norfolk, Virginia, United States
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
Phase 3
Completed
- Conditions
- Congenital FXIII DeficiencyCongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT01253811
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Columbus, Ohio, United States
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Phase 4
Completed
- Conditions
- Chronic Renal InsufficiencyDelivery SystemsGrowth Hormone Deficiency in ChildrenSmall for Gestational AgeTurner SyndromeChronic Kidney DiseaseGrowth Hormone DisorderFoetal Growth ProblemGenetic Disorder
- Interventions
- Device: Norditropin NordiFlex®
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 103
- Registration Number
- NCT01245374
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France
© Copyright 2025. All Rights Reserved by MedPath